A zinc-dependent thymic hormone that prolongs the hair growth phase in human follicles at picomolar concentrations—while its cousin thymosin beta-4 does the opposite

Thymulin is a nine-amino-acid metallopeptide—a tiny protein that requires zinc to function—produced by the thymus gland. Discovered by Jean-François Bach in 1977 under the name "Facteur Thymique Sérique" (serum thymic factor), its known role was exclusively immunological: T-cell differentiation, immune regulation, thymic signaling. Hair biology was not on anyone's radar.

That changed in 2012 when the Paus group at the University of Lübeck published a study in the Journal of Investigative Dermatology showing that human hair follicles not only express thymulin but respond to it—dramatically. At picomolar concentrations (10 pg/mL), thymulin prolonged anagen and stimulated follicular melanogenesis. In the same experiment, thymosin beta-4—a peptide the hair loss community associates with regrowth—shortened anagen. The thymic peptide hierarchy for hair was the opposite of what most people assumed.

This article examines thymulin's mechanism in hair biology, the clinical evidence that exists, the critical distinction between thymulin and thymosin beta-4, and what the zinc-dependency means for age-related hair thinning.

Quick Facts: Thymulin at a Glance

What Is Thymulin?

Pronunciation: THY-muh-lin

Your thymus gland sits behind your breastbone and is most active during childhood—it is the organ that teaches your immune cells how to do their job. One of its signature products is thymulin: a nine-amino-acid peptide that requires a single zinc atom to function. Without zinc, thymulin is biologically inert. With zinc, it becomes a potent signal for T-cell differentiation and immune regulation.

For decades, that was the entire story. Thymulin was an immune hormone, full stop. Its discoverer, Jean-François Bach, characterized it in 1977 under the French name "Facteur Thymique Sérique"—serum thymic factor. No one connected it to hair biology.

The connection emerged in 2012 from the laboratory of Ralf Paus, one of the most published researchers in hair biology. His group at the University of Lübeck tested several thymic peptides on living human hair follicles maintained in organ culture. The finding was striking: thymulin, at concentrations of just 10 picograms per milliliter—roughly a trillionth of a gram—prolonged the growth phase of human hair follicles and stimulated hair pigmentation. In the same experiment, thymosin beta-4 (the parent molecule of TB-500, a compound popular in the peptide community for tissue repair) shortened the growth phase. The thymic peptide family was not a single story for hair—it contained both a protagonist and an antagonist.

Origins and Discovery

Jean-François Bach first isolated thymulin in the early 1970s at Hôpital Necker in Paris while searching for circulating hormones produced by the thymus. By 1977, his group had characterized the nonapeptide and its zinc dependency, published the sequence, and demonstrated that it was produced exclusively by thymic epithelial cells. The compound was originally called FTS—Facteur Thymique Sérique—before being renamed thymulin by international consensus.

Bach's subsequent career focused entirely on thymulin's immunological role: T-cell maturation, autoimmune disease, immune aging. The peptide became a standard reference in thymic biology textbooks. No one investigated hair.

The hair story began when Natalia Meier and colleagues in Ralf Paus's group asked a simple question: do human hair follicles express thymic peptides? The answer, published in the Journal of Investigative Dermatology in 2012 (PMID 22402437), was yes—human follicles express thymulin, thymosin beta-4, and prothymosin alpha. More importantly, these peptides were not inert passengers. When added to human follicles in organ culture, thymulin prolonged anagen and stimulated melanogenesis, while thymosin beta-4 and prothymosin alpha shortened anagen and slowed growth.

The paper concluded with a sentence that understates its importance: thymulin is "a clinically interesting candidate hair growth stimulator." In hair biology terms, this was an invitation that has barely been accepted—only one clinical study has followed in the fourteen years since publication.

Mechanism of Action

Anagen Prolongation—The Core Effect

The hair growth cycle has three phases: anagen (active growth, lasting 2–7 years for scalp hair), catagen (regression, ~2 weeks), and telogen (rest, ~3 months). Every effective hair loss treatment—minoxidil, finasteride, low-level laser therapy—works at least partly by prolonging anagen. More time in anagen means longer, thicker hairs before they cycle out.

Thymulin prolongs anagen in human hair follicles maintained in organ culture at 10 pg/mL. This concentration is picomolar—astonishingly low by pharmacological standards. For comparison, most growth factors act at nanomolar concentrations (thousands of times higher). Thymulin's potency at picomolar levels suggests it is acting on a high-affinity receptor or signaling system that has not yet been fully characterized in follicular cells.

The downstream mechanism has not been mapped. The Meier et al. study demonstrated the functional outcome (anagen prolongation, melanogenesis stimulation) but did not identify the specific receptor, the intracellular signaling cascade, or the gene expression changes involved. This is an honest gap in the science—we know thymulin prolongs anagen, but we do not fully understand how.

Melanogenesis Stimulation

Beyond growth, thymulin stimulated hair follicle pigmentation in the Meier et al. study. This means it affects melanocyte function within the hair bulb—the cells that produce the pigment that gives hair its color. This is a separate effect from anagen prolongation and suggests thymulin may have applications beyond hair loss, potentially in premature graying. However, this pigmentation effect has not been studied beyond the single organ culture experiment.

Zinc Dependency—Biological and Clinical Implications

Thymulin's absolute requirement for zinc creates an important biological narrative:

The thymus involutes (shrinks) with age, reducing thymulin production. Simultaneously, zinc status declines in aging populations—zinc deficiency affects 15–25% of adults over 65. Since thymulin is inactive without zinc, age-related decline operates through two parallel mechanisms: less peptide produced and less zinc available to activate what remains.

Zinc deficiency independently causes telogen effluvium—diffuse hair shedding. The convergence is suggestive: declining thymulin production plus declining zinc availability may contribute to age-related hair thinning. This is a hypothesis, not a proven mechanism, but it is biologically coherent and explains why the clinical study used zinc-thymulin (the zinc-bound form) rather than the peptide alone.

The Thymosin Beta-4 Contrast

This distinction is critical for Cluster K readers: thymulin and thymosin beta-4 have opposite effects on human hair follicles. The JID study tested them side by side on the same human follicle preparations:

Thymulin (10 pg/mL) → prolonged anagen, stimulated melanogenesis. Thymosin beta-4 (10 ng/mL) → shortened anagen, slowed growth. Prothymosin alpha (10 ng/mL) → also slowed growth.

TB-500, the synthetic fragment of thymosin beta-4 that is widely used in the peptide community for tissue repair, has NOT been tested for hair in the same paradigm—but its parent molecule was tested and shortened hair growth. Anyone considering thymic peptides for hair should understand that these compounds are not interchangeable, and the one with the most community name recognition (TB-500) is derived from the one that shortened anagen.

Key Research Findings

Human Follicle Organ Culture (Meier et al., 2012 — PMID 22402437)

Published in the Journal of Investigative Dermatology, this study from the Paus group at the University of Lübeck is the cornerstone of thymulin's hair biology profile. Human scalp hair follicles were maintained in organ culture—removed from the scalp but kept alive and cycling in controlled conditions. This is the gold standard for preclinical hair biology: it uses human tissue, not animal models.

Key findings: Human follicles express thymulin, thymosin beta-4, and prothymosin alpha endogenously. Thymulin at 10 pg/mL prolonged anagen significantly compared to vehicle controls at days 7 and 9 of culture. Hair shaft elongation was stimulated. Follicular melanogenesis was enhanced. Thymosin beta-4 and prothymosin alpha had the opposite effect—shortened anagen, slowed growth.

The study's strength is its human tissue model, side-by-side comparison of multiple thymic peptides, and publication in a high-impact dermatology journal. Its limitation is that organ culture cannot replicate the full scalp environment—blood supply, immune milieu, hormonal context—that matters for clinical outcomes.

Clinical Study (Vickers, 2017 — DOI: 10.4172/2167-0951.1000147)

An open-label study of 18 subjects (17 male, 1 female) with androgenetic alopecia (Norwood 2–7, hair loss duration 3–40 years, mean age 55.4). Participants applied a topical zinc-thymulin water-based spray to the scalp for 4–10 months.

Results: 32% increase in vellus hair count. 23% increase in intermediate hair count. No adverse events—no irritation, redness, or systemic effects.

Limitations are significant: no placebo control (open-label), small sample size, published in Hair Therapy & Transplantation—an OMICS International journal that has faced criticism for editorial standards and is not indexed in PubMed. The data is consistent with the organ culture findings but cannot be considered definitive. A placebo-controlled trial in the same population would be necessary to confirm these results.

The Dutch Uncle assessment: the clinical data exists, says the right things, and is directionally consistent with the stronger lab data. But it was published in a journal that would not survive rigorous peer review scrutiny, and the absence of a control group means we cannot distinguish true effect from placebo, regression to the mean, or observer bias.

Safety Profile

Clinical Safety Data

The Vickers study (N=18, 4–10 months of topical use) reported no adverse events of any kind: no local irritation, no redness, no scalp reactions, no deterioration of existing hair, no systemic effects. For an open-label study, this is reassuring but not definitive—small sample sizes can miss uncommon adverse events.

Endogenous Peptide Advantage

Thymulin is a naturally occurring human peptide. Your body already makes it. Circulating levels peak in childhood and decline with age as the thymus shrinks. Topical application of a compound your body already produces at a route (scalp skin) that is unlikely to produce meaningful systemic absorption is a favorable safety profile on first principles. This does not eliminate risk, but it reduces the prior probability of unexpected toxicity compared to synthetic compounds with no endogenous counterpart.

Zinc Component

The active form is zinc-thymulin, so topical formulations contain zinc. Topical zinc at cosmetic concentrations is well-established as safe—zinc pyrithione is used in dandruff shampoos, zinc oxide in sunscreens. The zinc in thymulin formulations is at concentrations far below these established products.

Theoretical Concerns

Thymulin's primary function is immune modulation—specifically T-cell differentiation. Chronic high-dose topical application could theoretically alter local immune function in the scalp. This has not been observed in the available data, but the available data is limited to one 18-person study. Anyone with autoimmune conditions affecting the scalp should discuss thymulin use with a dermatologist.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Thymulin's human evidence is thin but higher quality than its quantity suggests—because the foundational study used human tissue, not mice.

Organ culture (human tissue, lab setting): The Meier et al. study in JID used living human hair follicles removed from scalp and maintained in culture. This is not "in vitro" in the typical sense—it is human tissue exhibiting real biological responses. The anagen prolongation and melanogenesis effects were statistically significant and came from a research group (Ralf Paus) whose work defines the field of experimental trichology. The limitation is that organ culture cannot replicate the full in vivo environment—vascular supply, immune milieu, hormonal cycling, sebaceous gland interaction.

Clinical data (one study, significant limitations): The Vickers study is the only clinical trial. Its results are directionally consistent with the organ culture findings—increased hair counts over months of topical use—but the absence of a placebo control, small N, and OMICS journal publication reduce its evidentiary weight substantially. In hair loss research, placebo response rates of 10–20% improvement in hair counts are common, so a 32% vellus increase without a control group leaves the actual treatment effect uncertain.

What is missing: any placebo-controlled trial, any replication of the organ culture findings by an independent group, any dose-response data in humans, any study of thymulin in alopecia areata (where the immunomodulatory mechanism would be most relevant), and any comparison to established treatments.

Legal and Regulatory Status

Thymulin is not FDA-approved for any indication—not hair loss, not immune support, not anything. No IND (investigational new drug) application has been filed, no clinical trials are registered, and no pharmaceutical company is developing thymulin for hair.

The compound is available from peptide vendors and specialty compounding pharmacies, typically as a topical scalp serum or spray. Some vendors also sell injectable zinc-thymulin for immune applications. In the US, purchasing thymulin for personal use occupies the same regulatory gray zone as most research peptides—legal to buy, unregulated in terms of quality or purity, and without FDA oversight for the claimed application.

WADA does not list thymulin on the 2025/2026 Prohibited Lists, so there is no sports regulatory concern for athletes using it topically.

Research Protocols

Human Follicle Organ Culture (Meier et al., 2012)

Human scalp hair follicles obtained from facelift surgery were microdissected and maintained in supplemented Williams' E medium. Follicles in anagen VI were treated with thymulin (10 pg/mL), thymosin beta-4 (10 ng/mL), prothymosin alpha (10 ng/mL), or vehicle. Hair cycle stage was assessed by morphology scoring at days 0, 3, 5, 7, and 9. Hair shaft elongation measured by micrography. Melanin content assessed by Masson-Fontana histochemistry.

Clinical Study (Vickers, 2017)

18 subjects with androgenetic alopecia (Norwood 2–7). Topical zinc-thymulin water-based spray applied to scalp daily for 4–10 months. Hair counts assessed by trichoscopy/phototrichogram—vellus, intermediate, and terminal categories. No placebo arm. No blinding. Endpoint: change in hair count from baseline.

Dosing in Published Research

The following table summarizes dosing protocols for Thymulin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Organ Culture Dosing (Meier et al., 2012)

Clinical Study Dosing (Vickers, 2017)

Note: The picomolar effective concentration in organ culture (10 pg/mL) is noteworthy. Most growth factors require nanomolar concentrations (1,000–1,000,000x higher). If thymulin truly operates at picomolar levels in vivo, very low topical concentrations may be sufficient—but the translation from organ culture concentration to effective topical scalp concentration has not been established.

Dosing — Community Protocols

Emerging Community Protocols

Community use of zinc-thymulin for hair is emerging but not yet mainstream. Available protocols from vendor guides and online communities include:

Daily topical application of zinc-thymulin scalp serum or spray, typically applied to clean dry scalp and massaged in. Some users combine with microneedling sessions (0.5–1.0 mm depth) at 1–2 week intervals. Combination products with GHK-Cu are available from some vendors.

Concentrations in commercial products are rarely disclosed in standardized units, making cross-product comparison impossible. The picomolar effective concentration from the organ culture study suggests that if vendors are using microgram-level concentrations in their topical products, there is likely excess compound—but whether this translates to clinical effect is unknown.

No standardized community dosing protocol exists. Peptidings presents the available information without endorsing any specific regimen. The compound has not been through safety testing at the concentrations used in commercial products.

Combination Stacks

Research into Thymulin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Thymulin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Thymulin is a compound that arrived at hair biology through an unexpected door. A thymic immune hormone—discovered in the 1970s, studied for decades in immunology—turned out to prolong the growth phase of human hair follicles at picomolar concentrations, while its cousin thymosin beta-4 (the parent molecule of TB-500) did the opposite. This differential effect, demonstrated on human tissue in a high-quality study from a leading trichology research group, is thymulin's strongest credential.

The clinical evidence is promising but limited. One small open-label study reported meaningful increases in hair counts with no adverse effects—results that are directionally consistent with the organ culture data but that cannot be considered definitive without placebo control and replication. The zinc dependency adds biological plausibility: as we age, we produce less thymulin and have less zinc to activate what remains, paralleling age-related hair thinning.

What thymulin needs, and does not yet have, is a properly controlled clinical trial. The biology says yes. The one clinical study says maybe. The answer lies in data that has not yet been generated.

Verdict Recapitulation

Verdict: Reasonable Bet. Real biological signal demonstrated in human tissue by a reputable group. Preliminary clinical signal with significant methodological limitations. Endogenous peptide with a clean safety profile. Zinc dependency creates biological coherence with age-related hair thinning. The mechanistic case is stronger than the clinical evidence, but both point in the same direction.

For readers considering Thymulin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Thymulin

Further Reading and Resources

If you want to go deeper on Thymulin, the evidence landscape for hair & follicle peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Hair & Follicle Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Thymulin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Meier NT, Haslam IS, Pattwell DM, Zhang GH, Mace KA, Hardman MJ, Philpott MP, Paus R. Short communication: thymic peptides differentially modulate human hair follicle growth. J Invest Dermatol. 2012;132(5):1516-1519. PMID 22402437
2. Vickers MA. Topical zinc-thymulin spray in androgenetic alopecia: an open-label clinical study. Hair Ther Transplant. 2017;7:147. DOI: 10.4172/2167-0951.1000147
3. Bach JF. Thymulin (FTS-Zn). Clin Immunol Immunopathol. 1989;46(2):174-184. PMID 2657247
4. Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008;14(5-6):353-357. PMID 18385818
5. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341(7):491-497. PMID 10441606

---